Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COTTONWOOD: Etrolizumab Extension in UC
NCT02118584Phase 3Terminated
- Sponsor
- Roche
- Start
- Sep 2014
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 42
01
Overview
Phase 3, open-label trial of Etrolizumab in ulcerative colitis (UC) (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score at 324 weeks, Percentage of Participants With Remission as Determined by the Mayo Clinic Score at 108 weeks and 3 more. Started Sep 2014; status: terminated.
02
Drugs
Etrolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02118584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02118584.